Showing 1871-1880 of 3460 results for "".
The Molecular Era in Melanoma Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-molecular-era-in-melanoma-treatment/21296/Melanoma Treatment Landscape Evolves
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-treatment-landscape-evolves/21314/The first agent to target the PD-1 pathway, pembrolizumab may prolong life expectancy in some patients.Analyzing Risk Factors for Subsequent Primary Melanomas
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-risk-factors-for-subsequent-primary-melanomas/21429/Charging Toward Stage 2 of Meaningful Use
https://practicaldermatology.com/topics/practice-management/charging-toward-stage-2-of-meaningful-use/21467/As the next stage of the Federal EHR incentive program is set to begin, the forecast remains uncertain.SPF Recommendations: Should They Change?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/spf-recommendations-should-they-change/21475/What is the minimum SPF dermatologists should be recommending to their patients?Protect Yourself Against System Breaches and Errors
https://practicaldermatology.com/topics/practice-management/protect-yourself-against-system-breaches-and-errors/21579/New reports of cyber-terrorism highlight the importance of EHR security.New Products and Pharmacologic Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-developments/21633/Complications of Biologic Therapy for Psoriasis: Part II
https://practicaldermatology.com/topics/psoriasis/complications-of-biologic-therapy-for-psoriasis-part-ii/22039/Therapeutic success requires clinicians to understand emerging and established safety concerns.Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manBeyond the Flare: Choosing the Right Systemic in Moderate-to-Severe Atopic Dermatitis
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/beyond-the-flare-choosing-the-right-systemic-in-moderate-to-severe-atopic-dermatitis/39728/